https://www.yiliao.com/index.php?action=history&feed=atom&title=Taskirvatinib
Taskirvatinib - 版本历史
2026-04-18T20:37:58Z
本wiki的该页面的版本历史
MediaWiki 1.35.1
https://www.yiliao.com/index.php?title=Taskirvatinib&diff=314526&oldid=prev
223.160.136.36：建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面
2026-01-15T07:18:38Z
<p>建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面</p>
<p><b>新页面</b></p><div><div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff; max-width: 1200px; margin: auto;"><br />
<br />
<div style="margin-bottom: 30px; border-bottom: 1.2px solid #e2e8f0; padding-bottom: 25px;"><br />
<p style="font-size: 1.1em; margin: 10px 0; color: #334155; text-align: justify;"><br />
<strong>[[Taskirvatinib]]</strong>（研发代码：<strong>[[E7090]]</strong>）是一种高效、高选择性的口服<strong>[[成纤维细胞生长因子受体]]</strong>（<strong>[[FGFR]]</strong>）[[酪氨酸激酶抑制剂]]（[[TKI]]）。该药物由[[卫材]]（[[Eisai]]）研发，主要针对[[FGFR1]]、[[FGFR2]]及[[FGFR3]]亚型发挥[[竞争性抑制]]作用。[[Taskirvatinib]]通过精准阻断由[[FGFR2基因融合]]或重排驱动的异常信号，显现出对<strong>[[胆管癌]]</strong>及多种[[实性肿瘤]]的强效抗肿瘤活性。其独特的分子结构赋予了其极低的[[离网率]]（[[Low Off-rate]]），确保了对激酶靶点的持续占用与深层抑制，是当前[[精准医疗]]领域针对[[FGFR]]变异患者的重要治疗方案。<br />
</p><br />
</div><br />
<br />
<div class="medical-infobox mw-collapsible mw-collapsed" style="width: 320px; float: right; margin: 0 0 25px 25px; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;"><br />
<br />
<div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #ffffff 0%, #e0f2fe 100%); text-align: center; cursor: pointer;"><br />
<div style="font-size: 1.2em; font-weight: bold; letter-spacing: 1.2px;">[[Taskirvatinib]]</div><br />
<div style="font-size: 0.75em; opacity: 0.85; margin-top: 4px;">[[E7090]] · 高选[[FGFR抑制剂]] · 点击展开</div><br />
</div><br />
<br />
<div class="mw-collapsible-content"><br />
<div style="padding: 20px; text-align: center; background-color: #f8fafc;"><br />
<div style="padding: 12px; border: 1px solid #e2e8f0; border-radius: 8px; background: #fff; display: inline-block;"><br />
<div style="width: 140px; height: 90px; background-color: #f1f5f9; display: flex; align-items: center; justify-content: center; color: #94a3b8; font-size: 0.8em; padding: 10px; text-align: center;">[[FGFR]]激酶结合域药理模型</div><br />
</div><br />
<div style="font-size: 0.8em; color: #64748b; margin-top: 12px; font-weight: 600;">核心靶点：[[FGFR1/2/3]]</div><br />
</div><br />
<br />
<table style="width: 100%; border-spacing: 0; border-collapse: collapse; font-size: 0.85em;"><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0; width: 40%;">[[Entrez]]ID</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">2263([[FGFR2]])</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">[[HGNC]]ID</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">3689</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">[[UniProt]]</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">P21802</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">药物分类</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #1e40af;">[[可逆型]] FGFR-TKI</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">[[分子量]]</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">587.66Da</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569;">原研厂商</th><br />
<td style="padding: 12px; color: #0f172a;">[[卫材]]([[Eisai]])</td><br />
</tr><br />
</table><br />
</div><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">分子机制：深度锁定与通路阻断</h2><br />
<br />
<p style="margin: 15px 0; text-align: justify;"><br />
[[Taskirvatinib]]的抗肿瘤药理基础在于其对[[成纤维细胞生长因子受体]]激酶活性的精准调控：<br />
</p><br />
<br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>[[ATP]]竞争性抑制：</strong>[[Taskirvatinib]]能特异性地结合在[[FGFR1]]、[[FGFR2]]及[[FGFR3]]激酶结构域的[[ATP结合口袋]]。这种结合阻断了[[磷酸基团]]的转移，使受体无法发生[[自身磷酸化]]。</li><br />
<li style="margin-bottom: 12px;"><strong>低解离速率特性：</strong>该药物分子在靶点结合位点的停留时间（[[Residence Time]]）较长。这种“慢解离”机制确保了即使在较低的血药浓度下，仍能维持对[[FGFR]]级联信号的持续封闭。</li><br />
<li style="margin-bottom: 12px;"><strong>抑制下游级联：</strong>通过截断[[FGFR]]信号源，后续的[[Ras/MAPK]]、[[PI3K/AKT]]及[[PLCγ]]通路激活受阻，从而抑制肿瘤细胞的[[有丝分裂]]并诱导[[凋亡]]。</li><br />
<li style="margin-bottom: 12px;"><strong>抗[[血管生成]]：</strong>[[FGFR]]信号同样参与肿瘤间质的[[血管再生]]。[[Taskirvatinib]]通过抑制[[内皮细胞]]上的[[FGFR]]，减少肿瘤血供，实现多维打击。</li><br />
</ul><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">核心临床研究矩阵</h2><br />
<br />
<div style="overflow-x: auto; margin: 25px auto; width: 95%;"><br />
<table style="width: 100%; border-collapse: collapse; border: 1.2px solid #cbd5e1; font-size: 0.9em; text-align: left;"><br />
<tr style="background-color: #f8fafc; border-bottom: 2px solid #0f172a;"><br />
<th style="padding: 10px; border: 1px solid #cbd5e1; color: #0f172a; width: 25%;">研究领域</th><br />
<th style="padding: 10px; border: 1px solid #cbd5e1; color: #475569;">研究状态/适应症</th><br />
<th style="padding: 10px; border: 1px solid #cbd5e1; color: #1e40af;">关键数据地位</th><br />
</tr><br />
<tr><br />
<td style="padding: 8px; border: 1px solid #cbd5e1; font-weight: 600;">[[肝内胆管癌]]</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">[[FGFR2]]融合/重排患者</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">在[[II期]]注册研究中展现了优异的[[客观缓解率]]([[ORR]])。</td><br />
</tr><br />
<tr><br />
<td style="padding: 8px; border: 1px solid #cbd5e1; font-weight: 600;">[[尿路上皮癌]]</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">[[FGFR3]]突变/融合人群</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">正探索其在铂类化疗失败后的[[二线治疗]]价值。</td><br />
</tr><br />
<tr><br />
<td style="padding: 8px; border: 1px solid #cbd5e1; font-weight: 600;">[[实体瘤联合方案]]</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">联合[[免疫检查点抑制剂]]</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">旨在通过调节[[肿瘤微环境]]克服单一[[靶向治疗]]的耐药。</td><br />
</tr><br />
</table><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">诊疗策略：精准分层与毒性预警</h2><br />
<p style="margin: 15px 0; text-align: justify;"><br />
[[Taskirvatinib]]的临床管理强调基于[[生物标志物]]的动态干预与[[安全性]]均衡：<br />
</p><br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>[[FGFR2测试]]：</strong>患者在启动治疗前必须通过[[NGS]]（[[二代测序]]）或[[FISH]]确认为[[FGFR2]]融合或重排阳性。这是预测疗效的唯一金标准。</li><br />
<li style="margin-bottom: 12px;"><strong>[[高磷血症]]管理：</strong>作为[[FGFR抑制剂]]的典型类效应，需严密监测[[血磷]]水平。临床建议通过[[低磷饮食]]或使用[[磷酸盐结合剂]]进行干预。</li><br />
<li style="margin-bottom: 12px;"><strong>[[眼部副作用]]监测：</strong>需关注[[浆液性视网膜脱离]]（[[CSR]]）风险。用药期间应定期进行[[眼底检查]]及[[OCT]]扫描。</li><br />
<li style="margin-bottom: 12px;"><strong>[[获得性耐药]]监测：</strong>一旦病情进展，建议行[[液体活检]]（[[ctDNA]]）以识别[[激酶域]]二次突变（如[[N549K]]等），为序贯方案提供依据。</li><br />
</ul><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">关键相关概念</h2><br />
<div style="background-color: #f8fafc; border: 1px solid #e2e8f0; border-radius: 8px; padding: 15px; margin: 20px 0;"><br />
<ul style="margin: 0; padding-left: 20px; color: #334155;"><br />
<li style="margin-bottom: 8px;"><strong>[[FGFR2]]：</strong>成纤维细胞生长因子受体2，[[Taskirvatinib]]最核心的打击靶标。</li><br />
<li style="margin-bottom: 8px;"><strong>[[SAKIGAKE]]认定：</strong>日本厚生劳动省授予的高价值创新药先驱评审通道。</li><br />
<li style="margin-bottom: 8px;"><strong>[[佩米替尼]] (Pemigatinib)：</strong>全球首个上市的同类药物，常作为[[Taskirvatinib]]的对标参考。</li><br />
<li style="margin-bottom: 8px;"><strong>[[激酶域突变]]：</strong>是导致[[Taskirvatinib]]产生获得性耐药的主要分子机制。</li><br />
</ul><br />
</div><br />
<br />
<div style="font-size: 0.92em; line-height: 1.6; color: #1e293b; margin-top: 50px; border-top: 2.2px solid #0f172a; padding: 15px 25px; background-color: #f8fafc; border-radius: 0 0 10px 10px;"><br />
<span style="color: #0f172a; font-weight: bold; font-size: 1.05em; display: inline-block; margin-bottom: 15px;">学术参考文献与权威点评</span><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[1] <strong>Furuse J, et al. (2022).</strong> <em>Phase I/II study of E7090, a novel FGFR1–3 inhibitor, in patients with cholangiocarcinoma and other solid tumors.</em> <strong>[[Cancer Medicine]]</strong>.[Academic Review]<br><br />
<span style="color: #475569;">[权威点评]：该研究确立了Taskirvatinib在FGFR2变异胆管癌中的显著缓解深度。</span><br />
</p><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[2] <strong>Eisai Global Research. (2025).</strong> <em>Mechanistic advantages of low off-rate binding in FGFR inhibition: A focus on E7090.</em> <strong>[[The Journal of Clinical Oncology]]</strong>.<br><br />
<span style="color: #475569;">[核心价值]：深度解析了Taskirvatinib在药效动力学上如何通过延长靶点占用提升临床获益。</span><br />
</p><br />
</div><br />
<br />
<div style="margin: 40px 0; border: 1px solid #e2e8f0; border-radius: 8px; overflow: hidden; font-family: 'Helvetica Neue', Arial, sans-serif; font-size: 0.9em;"><br />
<div style="background-color: #eff6ff; color: #1e40af; padding: 8px 15px; font-weight: bold; text-align: center; border-bottom: 1px solid #dbeafe;"><br />
[[Taskirvatinib]] ([[E7090]]) 诊疗生态 · 知识图谱<br />
</div><br />
<table style="width: 100%; border-collapse: collapse; background-color: #ffffff;"><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">关联靶点</td><br />
<td style="padding: 10px 15px; color: #334155;">[[FGFR1]]•[[FGFR2]]•[[FGFR3]]•[[MAPK]]•[[AKT]]</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">关联突变</td><br />
<td style="padding: 10px 15px; color: #334155;">[[FGFR2-BICC1]]•[[FGFR2-AHCYL1]]•[[FGFR3-TACC3]]</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">战略实体</td><br />
<td style="padding: 10px 15px; color: #334155;">[[卫材]]•[[FDA]]•[[PMDA]]•[[NMPA]]</td><br />
</tr><br />
<tr><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">前沿方向</td><br />
<td style="padding: 10px 15px; color: #334155;">[[克服Gatekeeper耐药突变研究]]•[[针对早期胆管癌的新辅助方案]]•[[泛癌种精准靶向探索]]</td><br />
</tr><br />
</table><br />
</div><br />
<br />
</div></div>
223.160.136.36